Elisa Sensi
Azienda Ospedaliera Universitaria Pisana(IT)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Genetic factors in colorectal cancer, BRCA gene mutations in cancer, Cancer Genomics and Diagnostics
Most-Cited Works
- → FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study(2015)1,081 cited
- → Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study(2015)318 cited
- → Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial(2010)240 cited
- → FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer(2013)185 cited
- → Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases(2010)184 cited
- → BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection(2015)169 cited
- → Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer(2014)157 cited
- → Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study(2017)117 cited
- → Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations(2002)110 cited
- → Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO(2018)107 cited